December 18, 2007 09:29 ET

CDEX Demonstrates ValiMed™ and Meth Scanner; Introduces New Fentanyl Validation System

TUCSON, AZ--(Marketwire - December 18, 2007) - CDEX, Inc. (OTCBB: CEXI) demonstrated its ValiMed™ Medical Validation System and Meth Scanner™ to numerous national and international hospital executives, pharmacists, distributors, medical equipment manufacturers and industry representatives at the ASHP trade show in the Sands Expo Center in Las Vegas, Nevada. Pascal Pouligny, CDEX VP of International Sales and Marketing headquartered in Paris, France, demonstrated ValiMed to an enthusiastic international audience. Xavier Guix, Marketing Director at Grifols International stated, "ValiMed has great promise for the international market. By validating the medication itself and not simply the packaging provides a whole new level of patient safety that we are exploring with great interest." Grifols International, with headquarters in Barcelona, Spain, is a leading, worldwide supplier of medical products and services.

The CDEX Team of Stuart Poteet, Tim Shriver, Jr., Cynthia Sampson, Malcolm Philips, Pascal Pouligny and Tim Shriver, also demonstrated the Meth Scanner to interested representatives including the Governor of Nevada Jim Gibbons and his wife, Dawn Gibbons, and unveiled a new, low-cost Fentanyl Validation System for strengthening procedure to prevent narcotic diversion in medical facilities. In addition, Tim Shriver, CDEX Senior VP of Technical Operations, responded to inquiries from equipment manufacturers about the integrated use of the CDEX technology in medical equipment that distributes controlled substances and equipment that automatically compounds medications. "The continued expansion of the ValiMed Signature Library offers us the opportunity to consider integration of our technology into related medical products," said Mr. Shriver. "This is an exciting expansion that we looked at three years ago and are now ready to explore aggressively."

ValiMed™ uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to its expected CDEX Library signature and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation. ValiMed is currently saving lives in hospitals across the nation.

About CDEX, Inc.

CDEX, a technology development company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets. Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit and or contact Malcolm Philips ( or Stuart Poteet ( at 520.745.5172 X 210 or 202.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the Protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Sec. There is no obligation to publicly update any forward-looking statements.

Contact Information